MESI Medical was founded in 2010 and is a pioneer in simplifying and digitizing diagnostic workflows in all healthcare environments, from general practices to assisted care. The company developed the ‘mTablet’, a tablet that bundles data that is collected through the use of MESI’s own medical assessment products, such as blood pressure cuffs and ECG.
SHS, a leading investor in the healthcare sector, has made an investment in MESI. SHS is a German private equity company dedicated to invest in innovative growth companies and SMEs in the MedTech and Life Science space. With their investments, SHS helps to shape European champions in their respective healthcare segments or support them in their further expansion.
MESI’s mission is to develop innovations for early discovery of medical conditions. In this, it focuses on digital diagnostics to help doctors collect, understand and contextualize the data relevant for making diagnoses and other medical decisions.
After its founding in 2010, MESI improved arterial assessment by making the detection of Peripheral Arterial Disease easy and accessible already at primary care level. The company now strives to do the same for other cardiovascular conditions. Just in 2022 in primary care alone, their technology led to identification of disease cases in over 220,000 patients, and more than 40,000 cases were shared digitally with a specialist for a second opinion, improving outcomes and saving time and cost for doctors and patients.
The investment by SHS was provided after a strong growth and medtech entrepreneur Oliver Heine joining the company as an investor and strategic advisor in 2022. Empowered by the investment and a strong advisory board, MESI will be able to expand its sales organisation and its portfolio of products and services. This includes AI powered predictive applications and makes a real contribution to the digitization of healthcare.
“We are excited to partner with MESI, a company that has already demonstrated its commitment to improving patient outcomes and digitizing healthcare through innovation.” – Sascha Alilovic, Managing Partner SHS
“We are thrilled that our European and global efforts have resulted in a partnership with SHS. The aim of our innovation is to facilitate access to relevant diagnostic data. This speeds up the diagnostic process for the patient, resulting in faster treatment and prevention of adverse events. The SHS investment will allow us to continue developing new ways for healthcare professionals to predict, diagnose, and manage various conditions with greater accuracy and efficiency.” – Jakob Šušterič, CEO MESI
Carlsquare acted as the exclusive financial advisor to MESI.
